Menu
  • The inaugural US E-Cigarette Summit was held in Washington DC, on Monday May 8, 2017 and welcomed over 250 people
  • Registration for the UK E-Cigarette Summit 2017 is now open

Science, Regulation and Public Health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life.  Despite decades of successful tobacco control efforts, we are still a long way from ending the smoking epidemic.

The emergence of e-cigarettes, which deliver nicotine but without the vast range of carcinogens and toxins found in combustible tobacco products has created one of the most controversial and contentious public health issues of a generation, with divisions appearing within longstanding professional alliances in both Tobacco Control and Public Health communities, despite a continued shared goal of protecting public health and ending the smoking epidemic.

The E-Cigarette Summit provides a  neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

2017 Key Topics include:

  • How safe are e-cigarettes – current clinical trials – what do we know and what do we still need to find out
  • Do e-cigarettes undermine current tobacco control measures or offer new opportunities
  • Evidence on Gateway and current use, what is the available data and how should it be interpreted.
  • Use of e-cigarettes in public what are the concerns
  • How will regulation affect the current market and products available. Intended and unintended consequences
  • Advertising and promotion, what are the issues and how should these be addressed
  • Conflicting interests that arise from the dual corporate ownership of tobacco products and harm reduction products
  • What should cessation practitioners be saying to current smokers?

Confirmed Speakers/Panel Presenters

Thomas J. Glynn, PhD – Consulting Professor, Stanford Prevention Research Center, Stanford University School of Medicine

Prof Ken Warner – Professor, Health Management & Policy, School of Public Health, University of Michigan

Andrea C. Villanti – Director Regulatory Science & Policy, Schroeder Institute for Tobacco Research and Policy Studies.

Prof Linda Bauld – Professor of Health Policy, University of Stirling, Cancer Research UK and UKCTAS

Robin J. Mermelstein, PhD – Professor of Psychology and Director Institute for Health Research and Policy ( IHRP), University of Illinois, Chicago

Raymond Niaura, Ph.D – Director of Science at the Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative

Judith J. Prochaska, PhD, MPH – Associate Professor of Medicine (Stanford Prevention Research Center)

Prof Neal Benowitz – Professor of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco, USA

Prof. Jonathon Foulds – Professor of Public Health Sciences and Psychiatry, Penn State Tobacco Center of Regulatory Science , Cancer Institute

Dr Konstantinos Farsalinos – Researcher, Onassis Cardiac Surgery Center Greece, University of Patras, Greece

Joanna Cohen – Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health

Matthew L. Myers – President, Campaign for Tobacco-Free Kids

Deborah Arnott – Chief Executive, Action on Smoking & Health (ASH), UK

Kevin Walton, PhD – Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, NIH

David Graham – President and Managing Partner, Reveritas Group

Eric N. Lindblom JD – Director for Tobacco Control and Food and Drug Law at the O’Neill Institute for National and Global Health Law

Prof Ann McNeill – Professor of Tobacco Addiction – UK Centre for Tobacco and Alcohol Studies (UKCTAS) Kings College London

Dr. James Davis – Medical Director, Duke Center for Smoking Cessation, Assistant Professor of Medicine

Prof Dorothy Hatsukami – Professor, Department of Psychiatry, Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota

AG Tom Miller –The Attorney General of Iowa